Pfizer plans fight to hold share against generic cholesterol drugs

10/17/2005 | NYTimes.com

Insurers and government agencies look forward to billions of dollars in savings when they can move patients from Pfizer's cholesterol drug Lipitor to less expensive generics such as Merck's Zocor and newer generics expected to hit the market. Merck's patent on Zocor expires in June; Pfizer plans to fight the migration to generic versions of Zocor by using its marketing muscle and clinical data showing Lipitor is more effective than the generics.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ